Cationic Cell-Penetrating Peptides Are Potent Furin Inhibitors

Bruno Ramos-Molina1, Adam N. Lick1, Amir Nasrolahi Shirazi2, Donghoon Oh2, Rakesh Tiwari2, Naglaa Salem El-Sayed2, Keykavous Parang2, Iris Lindberg1*

1 Department of Anatomy and Neurobiology, School of Medicine, University of Maryland-Baltimore, Baltimore, Maryland, United States of America, 2 Chapman University, School of Pharmacy, Irvine, California, United States of America

* ilindberg@som.umaryland.edu

Abstract

Cationic cell-penetrating peptides have been widely used to enhance the intracellular delivery of various types of cargoes, such as drugs and proteins. These reagents are chemically similar to the multi-basic peptides that are known to be potent proprotein convertase inhibitors. Here, we report that both HIV-1 TAT47-57 peptide and the Chariot reagent are micromolar inhibitors of furin activity in vitro. In agreement, HIV-1 TAT47-57 reduced HT1080 cell migration, thought to be mediated by proprotein convertases, by 25%. In addition, cyclic polyarginine peptides containing hydrophobic moieties which have been previously used as transfection reagents also exhibited potent furin inhibition in vitro and also inhibited intracellular convertases. Our finding that cationic cell-penetrating peptides exert potent effects on cellular convertase activity should be taken into account when biological effects are assessed.

Introduction

Cationic peptides present within envelope proteins are used by many viruses to gain entry into host cells. These peptides, which efficiently pass through the plasma membrane and either remain in the cytoplasm or reach the nucleus, are frequently used as protein transduction reagents (reviewed in [1,2]). The use of cell-penetrating peptides (CPPs) has even been proposed as a drug delivery tool for therapeutic molecules in various diseases, for example cancer [3]. One of the most studied CPPs over the past decade has been the human immunodeficiency virus type 1 (HIV-1) transcriptional activator, the TAT protein, a virally-encoded regulatory factor essential for viral replication [4]. Many different studies have now confirmed that the highly basic region located between residues 47–57 is necessary and sufficient for intracellular import and delivery of a variety of proteins and nucleic acids [3,5,6]. In addition to the TAT peptide, numerous natural and synthetic CPPs have been described in the literature (i.e. penetratin [7], Pep-1/Chariot [8], and polyarginine-containing peptides [9,10,11]) and are now commercially available. Variants on this theme include certain cyclic polyarginine peptides with high cell permeability and stability which have been recently used for the delivery of a
wide range of cargoes, including anticancer and antiviral drugs; and phosphopeptides [12,13,14].

The proprotein convertase (PC) furin is a ubiquitous calcium-dependent endoprotease that is involved in the cleavage of a variety of precursor proteins at strings of basic amino acids within the constitutive secretory pathway. Polyarginines are known to constitute potent inhibitors of furin and other members of the family of the proprotein convertases. For example, hexa-D-arginine amide (D6R) and nona-D-arginine amide (D9R) exhibit inhibition constants against furin and other convertases in the nanomolar range [15,16]. In agreement, polyarginine-based peptides have been shown to block furin-mediated activation of various bacterial toxins, both in vivo and in vitro [17,18,19,20,21]. Molecular modeling studies support the idea that polyarginine binding is likely mediated by the acidic substrate binding cleft within the furin catalytic domain [15].

In order to assess the possibility that CPPs used for the intracellular delivery of proteins and drugs might exert side effects on cellular proprotein convertases, in the study reported below we have investigated their inhibitory effects on convertase activity, both in vitro and within cells.

Materials and Methods

Materials

Soluble human furin was purified from the conditioned medium of stably-transfected, methotrexate-amplified CHO DG44 cells, as previously described [15]. Nona-D-arginine amide (D9R) was synthesized by Pepceuticals (New Orleans, LA) and purified by reverse-phase HPLC to greater than 99% purity. The HIV-1 TAT47-57 peptide was purchased from Creative Peptides (Shirley, NY). The Chariot reagent was purchased from Active Motif (Carlsbad, CA). The Chariot and HIV Tat peptides were not terminally blocked. All cyclic polyarginine peptides used in this work ([W5R4C], [WR]5, C12-[-R5], and W4-[-R5]) were synthesized using a Fmoc/tBu solid-phase peptide synthesis strategy according to a previously described procedure [13,22]. The first two peptides ([W5R4C]; [WRWRWRWRWC]) and ([WR]5; [WRWRWRWRW]) are cyclic and thus have no N- and C-terminal modifications. The third peptide (C12-[-R5]; dodecanoyl-[KRRRRR]) is also cyclic and does not contain N or C-terminal modifications. The fourth peptide (W4-[-R5]; N-acetyl-WWWW-[KRRRRR]) is N-terminally acetylated.

Enzyme assays and determination of Ki values

The furin assay was performed in 96-well polystyrene microtiter plates in a final volume of 50 μl, containing 100 mM HEPES, pH 7.0, 5 mM CaCl2, 0.1% Brij 35, 0.1% NaN3, and 0.1 mg/ml BSA. The substrate p-Glu-Arg-Thr-Lys-Arg-4-methylcoumaryl-7-amide (pERTKR-mca; Peptide Institute, Lexington, KY) was used at a final concentration of 100 μM. Furin was used at a final concentration of 20 nM. Reaction mixtures were incubated at 37°C and fluorescence measurements (380 nm excitation, 460 nm emission) were taken under kinetic conditions every minute for 60 min in a SpectraMax M2 microplate reader. For Ki assays, serial dilutions of compounds were performed to give final concentrations between 10 nM and 10 μM in 50 μl. After a 30-min preincubation at room temperature, 100 μM of pERTKR-methylaminocoumarin (mca) was added, and residual enzyme activities were monitored by measuring mca fluorescence intensity. Data were analyzed using Prism 5 as described previously [23]. Due to cost considerations, Ki determinations were not performed for the HIV TAT peptide or for the Chariot reagent.
Cell migration assays

HT1080 fibrosarcoma cells (ATCC# CCL-121) were cultured to 80% confluence in growth medium (MEM (Earle’s salts + L-glutamine) 10% FBS, 1:100 non-essential amino acids (NEAA), 1 mM sodium pyruvate, 500 U/ml penicillin-streptomycin, and 1% gentamycin; Life Technologies). Cells were plated in an Oris Cell Migration Assay (Platypus Technologies) 96-well plate at 10^5 cells per well, following the manufacturer’s protocol. The next day, the growth medium was removed, the wells rinsed with PBS, and the cells were incubated in assay medium MEM (Earle’s salts + L-glutamine) containing 10% heat-inactivated FBS, 1:100 NEAA, 1 mM sodium pyruvate, 500U/ml penicillin-streptomycin, and 1% gentamycin in the presence or absence of inhibitors for 24 h at 37°C and 5% CO₂. After incubation cells were rinsed with PBS (calcium and 20 mM HEPES, pH 7.4, as per the manufacturer’s protocol), and incubated with the Live / Dead Cell Stain Kit containing 2 μM calcein AM and 4 μM ethidium homodimer (EthD-1) for 30 min at 37°C and 5% CO₂. Fluorescence was then measured at 485/528 nm excitation/emission for calcein AM, and 530/645 nm for EthD-1. The experiments were independently repeated three times.

Cytotoxicity assay

In order to assess the potential cytotoxic effects of each compound, cytotoxicity assays were performed in CHO DG44 cells (obtained from Lawrence Chasin, Columbia University and grown in Ham’s F12 medium with 10% bovine serum) using the mitochondrial dye WST-1 (Roche). Cells were seeded into 96-well plates to achieve 50% confluence the next day, and then incubated with each compound or with vehicle for 24 h. After incubation with inhibitors, cells were further incubated for 4 h with 10 μl of WST-1 reagent per well, and the absorbance was measured at 450 and 600 nm. The experiments were repeated independently 2–3 times using triplicate wells.

SEAP activity assays

CHO-GRAPfurin cells expressing the hybrid reporter protein GRAPfurin, consisting of the secreted alkaline phosphatase (SEAP) protein fused to a Golgi retention signal and a specific furin recognition/cleavage site [24,25], were plated in 96-well plates and incubated with Opti-Mem containing 100 μM of either drug or vehicle for 16–20 h. The medium was collected, centrifuged, and heated for 30 min at 65°C to inactivate non-relevant phosphatases. To test SEAP activity, 2.5 μl of heated medium was mixed with 100 μl of assay buffer (100 mM Tris-HCl, pH 10, 100 mM NaCl, 5 mM MgCl₂) and 100 μl of 36 μM 4-methylumbelliferyl phosphate (MUP), a phosphatase substrate, made in 50 mM Tris-HCl, pH 10. Fluorescence was measured every 20 seconds after excitation at 365 nm and recording emission at 460 nm at 37°C for 1 h. Since SEAP released from the tethered furin reporter is secreted, SEAP levels in the medium are proportional to the activity of Golgi furin [24,25]. The experiments were independently repeated three times using triplicate wells per condition.

Results

The HIV-1 TAT47-57 and Chariot peptides inhibit furin activity in vitro

To determine the effect of the polybasic carrier peptide HIV-1 TAT47-57 and the Chariot transfection reagent (Table 1) on furin activity, we performed in vitro enzyme assays. The peptides were preincubated with soluble human furin in assay buffer and then further incubated with the fluorogenic substrate pERTKR-mca, as described in "Materials and Methods". Fig 1A shows that the HIV-1 TAT47-57 peptide produced substantial furin inhibition at micromolar
concentrations (~60% at 10 μM). The inhibition of furin activity was nearly complete at the higher concentration of 100 μM (Fig 1A). The Chariot reagent also inhibited furin at micromolar concentrations (~20% at 10 μM; ~60% at 100 μM), although much less potently than the HIV-1 TAT47-57 peptide (Fig 1B). This difference may be attributable to the greater number of arginine residues present in the HIV-1 TAT47-57 peptide sequence (Table 1). It should be noted that the amounts of Chariot reagent used in these assays are within the range of the manufacturer’s suggestions for use as a protein transfection adjuvant (10 μM to 100 μM).

HIV-1 TAT peptide inhibits cancer cell migration

Because of its inhibitory potency in vitro against furin, as well as its known cell permeability, we then analyzed the inhibitory capacity of the HIV-1 TAT47-57 peptide against cancer cell migration, a process dependent on the activity of cellular convertases. We incubated HT1080 fibrosarcoma cells together with a non-toxic quantity of the HIV-1 TAT47-57 peptide (10 μM). Fig 2 shows that incubation of cells with HIV-1 TAT47-57 resulted in significant inhibition of cell migration, similar to that obtained with the multi-Leu convertase inhibitor peptide [26,27].

Cyclic polyarginine peptides are potent furin inhibitors in vitro

Stable and cell-permeable cyclic polyarginine peptides, such as the C12-[R5] compound, have been reported to exhibit little cytotoxicity [13,14]. Given the known inhibition of furin activity by polyarginines [28] we examined the inhibitory capacity of these cyclic compounds on furin.

### Table 1. Cationic cell-penetrating peptides tested as furin inhibitors.

| Name    | Origin  | Sequence       |
|---------|---------|----------------|
| TAT47-57| HIV-1 protein | YGRKKRRQRRR |
| Chariot | Synthetic | KETWWETWTEWSQPKKKRKV |

doi:10.1371/journal.pone.0130417.t001

![Fig 1. Inhibition of furin by the cationic peptides HIV-1 TAT47-57 and Chariot.](https://doi.org/10.1371/journal.pone.0130417.g001)
activity in vitro. The structures of the cyclic polyarginine peptides tested in this work are shown in Fig 3. These compounds exhibited high inhibitory potency in vitro, with Ki values between 1 μM and 0.1 μM (Table 2).

Cyclic polyarginine peptides inhibit intracellular convertases

In agreement with a previous study [13], we found no cytoxicity after a 24-h incubation of CHO cells with cyclic polyarginine compounds at 1 μM (Fig 4A). Interestingly, all compounds exhibited significant inhibition of intracellular convertase activity in the TGN at this concentration, as demonstrated using an assay based on the release of SEAP from a Grap-furin Golgi reporter tethered to membranes via a furin consensus cleavage site [24] (Fig 4B). While this assay is not specific for furin—as opposed to other constitutively-expressed convertases such as PACE4—these SEAP assay results correlate well with inhibition results obtained in vitro, as the most effective compound in cells (W₄-[R]₅) was also the most potent furin inhibitor in vitro (Table 2).

Discussion

Cationic cell-penetrating peptides (CPPs) have been broadly used for the delivery of various types of molecular cargoes such as small molecule drugs, siRNAs, and phosphopeptides...
Most of these compounds contain a polybasic domain responsible for transport into the intracellular space. The initial, and still the best characterized CPP, is the trans-acting activator of transcription (TAT) peptide derived from the human immunodeficiency virus [30,31]. Exhaustive analyses have demonstrated that the sequence responsible for its cellular uptake consists of the arginine-rich region YGRKKRRQRRR located between residues 47 and 57 [3,29]. The relevance of the arginine residues to uptake was clearly demonstrated by the assay of truncated analogs of HIV-1 TAT47-57 [10]. The practical applications of CPPs are furin inhibitors.

Fig 3. Chemical structures of cyclic polyarginine peptides tested as furin inhibitors.

doi:10.1371/journal.pone.0130417.g003
the use of this peptide in vivo have been previously established [32]. In this latter study, Schwarze and colleagues injected a fusion protein composed of HIV-1 TAT47-57 and β-galactosidase intraperitoneally into mice, and subsequently detected significant local β-galactosidase activities in most of the tissues analyzed. Aside from HIV-1 TAT47-57, a variety of other polyarginine-containing peptides have been proposed for the intracellular delivery of nucleic acids, proteins, and drugs [33,34]. Indeed, several groups have proposed the use of cationic transfection peptides as a means of delivering therapeutic species in the treatment of human diseases such as cancer [3,35].

Simple arginine-rich peptides themselves have been also proposed for use as transfection reagents since they enter cells efficiently [9,10,36,37,38]. However, polyarginine-containing peptides are known to potently inhibit several members of the proprotein convertase (PC) family, such as furin, PC5/6, PACE4 and PC7 [16,28,39,40,41]. The results shown here strongly support the idea that the HIV-1 TAT47-57 peptide and Chariot transfection reagent do possess the off-target effect of inhibiting furin (and likely other proprotein convertases). Interestingly, we show here that the TAT47-57 CPP also inhibits cancer cell migration. These results can be potentially be linked to effects on cellular convertase activity, since numerous studies have

Table 2. Ki values of the synthetic cyclic peptides tested as furin inhibitors.

| Name           | Peptide sequence             | Ki (μM)   |
|----------------|------------------------------|-----------|
| [W₅R₄C]       | WRWRWRWRWC                   | 0.34 ± 0.02 |
| [WR]₅         | WRWRWRWRWR                   | 0.98 ± 0.14 |
| C₁₂-[R₅]      | Dodecanoyl-[KRRRRR]          | 1.02 ± 0.40 |
| W₄-[R₅]       | N-acetyl-WWWW-[KRRRRR]       | 0.10 ± 0.14 |
| Hexa-D-arginine| mrrrr-amide                  | 0.106 ± 0.010 |
| Nona-D-arginine| mrrrrrr-amide                | 0.0013 ± 0.002 |

The data for hexa-D-arginine (D6R) and nona-D-arginine (D9R) are taken from [28] and [15] respectively.
described furin-mediated activating cleavage of certain metalloproteinases, i.e. stromelysin-3 and proMT1-MMP, whose activation then results in extracellular matrix degradation [25,42,43,44]. The convertase-inhibiting property of the HIV-1 TAT47-57 peptide might in fact assist the therapeutic efficacy of any delivered anticancer cargo via the inhibition of the elevated intracellular convertase activity known to be associated with tumor development and metastasis (reviewed in [45]).

In addition to the linear CPPs, a number of synthetic cyclic polyarginines with efficient cell permeability have also been recently proposed as CPPs to assist the intracellular delivery of proteins, drugs and nucleic acids [12,14,46,47,48,49,50]. Our results show that these cyclic polyarginines also represent potent inhibitors of furin activity in vitro. Similar to previous studies [13,14], the treatment of cells with cyclic polyarginines for 24 h was not cytotoxic. In agreement with their efficient uptake and likely low rates of intracellular degradation, these cyclic compounds all inhibited intracellular convertases, as assessed by blockade of the release of a furin cleavage reporter molecule. Cyclic polyarginines may thus be of use in applications where intracellular furin inhibition is advantageous, such as the prevention of tumor cell proliferation and migration mentioned above.

Off-target effects of cationic CPPs (i.e. on biological activities other than transport) have been previously cataloged in a recent review [2] and include a variety of biological effects, such as oxidative stress effects, responsiveness to heparan sulfate, lipid remodeling, and actin rearrangement. Interestingly, the only prior study that has addressed the interaction of CPPs with proprotein convertases concluded that furin may act to inactivate the TAT7-57 peptide, although furin-mediated inactivation was not directly demonstrated in this work [51]. Our data support a contradictory conclusion: that TAT47-57 acts to inhibit intracellular furin and/or other convertases.

In conclusion, the data presented here demonstrate that a variety of cell-penetrating peptides (HIV-1 TAT47-57, Chariot, and cyclic polyarginine peptides) which are widely used as protein transduction agents can significantly inhibit cellular convertase activity. While not necessarily deleterious (for example in anti-cancer applications; [45]), this off-target effect must be taken into account in in vivo therapeutic applications of polyarginine-containing CPP compounds.

Acknowledgments

We are grateful to Dr. A. Rehemtulla (U. Michigan) for providing the GRAPfurin reporter cell system.

Author Contributions

Conceived and designed the experiments: BR ANL ANS KP IL. Performed the experiments: BR ANL IL. Analyzed the data: BR ANL ANS KP IL. Contributed reagents/materials/analysis tools: ANS DO RT NSE KP IL. Wrote the paper: BR KP IL.

References

1. Joliot A, Prochiantz A (2004) Transduction peptides: from technology to physiology. Nat Cell Biol 6: 189–196. PMID: 15039791
2. Verdurmen WP, Brock R (2011) Biological responses towards cationic peptides and drug carriers. Trends Pharmacol Sci 32: 116–124. doi: 10.1016/j.tips.2010.11.005 PMID: 21167610
3. Wadia JS, Dowdy SF (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57: 579–596. PMID: 15722165
4. Wadia JS, Dowdy SF (2003) Modulation of cellular function by TAT mediated transduction of full length proteins. Curr Protein Pept Sci 4: 97–104. PMID: 12678849
5. Vivès E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 16010–16017. PMID: 9188504

6. Rudolph C, Plank C, Lausier J, Schillinger U, Müller RH, et al. (2003) Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 278: 11411–11418. PMID: 12519756

7. Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444–10450. PMID: 8144628

8. Gros E, Deshayes S, Morris MC, Aldrian-Herrada G, Depollier J, et al. (2006) A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta 1758: 384–393. PMID: 16545342

9. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, et al. (2001) Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276: 5836–5840. PMID: 11084031

10. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, et al. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Nat Acad Sci U S A 97: 13003–13008. PMID: 11087855

11. Moutal A, Francois-Moutal L, Brittain JM, Khanna M, Khanna R (2014) Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphiphilic cell penetrating peptides. Front Cell Neurosci 8: 471. doi: 10.3389/fncel.2014.00471 PMID: 25674050

12. Nasrolahi Shirazi A, Mandal D, Tiwari RK, Guo L, Lu W, et al. (2013) Cyclic peptide-capped gold nanoparticles as drug delivery systems. Mol Pharm 10: 500–511. doi: 10.1021/mp300448k PMID: 22998473

13. Oh D, Nasrolahi Shirazi A, Northup K, Sullivan B, Tiwari RK, et al. (2014) Enhanced cellular uptake of short polycationic peptides through fatty acylation and cyclization. Mol Pharm 11: 2845–2854. doi: 10.1021/mp500203e PMID: 24978295

14. Nasrolahi Shirazi A, Tiwari RK, Oh D, Banerjee A, Yadav A, et al. (2013) Efficient delivery of cell impermeable phosphopeptides by a cyclic peptide amphiphile containing tryptophan and arginine. Mol Pharm 10: 2008–2020. doi: 10.1021/mp400046u PMID: 23537165

15. Kaczprzak MM, Peinado JR, Than ME, Appel J, Henrich S, et al. (2004) Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine. J Biol Chem 279: 36788–36794. PMID: 15197180

16. Fugere M, Appel J, Houghten RA, Lindberg I, Day R (2007) Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol Pharmacol 71: 323–332. PMID: 17012622

17. Sarac MS, Cameron A, Lindberg I (2002) The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immnu 70: 7136–7139. PMID: 12438396

18. Sarac MS, Peinado JR, Leppla SH, Lindberg I (2004) Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect Immun 72: 602–605. PMID: 14688144

19. Peinado JR, Kaczprzak MM, Leppla SH, Lindberg I (2004) Cross-inhibition between furin and lethal factor inhibitors. Biochem Biophys Res Commun 321: 601–605. PMID: 15358148

20. Gagnon H, Beauchemin S, Kwiatkowska A, Couture F, D’Anjou F, et al. (2014) Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin. J Med Chem 57: 29–41. doi: 10.1021/jm400633d PMID: 24359257

21. Becker GL, Lu Y, Hardes K, Strehlow B, Levesque C, et al. (2012) Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem 287: 21992–22003. doi: 10.1074/jbc.M111.332643 PMID: 22539349

22. Nasrolahi Shirazi A, Tiwari R, Chhikara BS, Mandal D, Parang K (2013) Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs. Mol Pharm 10: 488–499. doi: 10.1021/mp3004034 PMID: 23301519

23. Vivoli M, Caulfield TR, Martinez-Mayorga K, Johnson AT, Jiao GS, et al. (2012) Inhibition of prohormone convertases PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives. Mol Pharmacol 81: 440–454. doi: 10.1124/mol.111.077040 PMID: 22169851

24. Coppola JM, Hamilton CA, Bhojani MS, Larsen MJ, Ross BD, et al. (2007) Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. Anal Biochem 364: 19–29. PMID: 17316541

25. Coppola JM, Bhojani MS, Ross BD, Rehemtulla A (2008) A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 10: 363–370. PMID: 18392131
26. Levesque C, Fugere M, Kwiatkowska A, Couture F, Desjardins R, et al. (2012) The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J Med Chem 55: 10501–10511. doi: 10.1021/jm301117f PMID: 23126600

27. Longuespee R, Couture F, Levesque C, Kwiatkowska A, Desjardins R, et al. (2014) Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Transl Oncol.

28. Cameron A, Appel J, Houghten RA, Lindberg I (2000) Polyarginines are potent furin inhibitors. J Biol Chem 275: 36741–36749. PMID: 10958789

29. Foerg C, Merkle HP (2008) On the biomedical promise of cell penetrating peptides: limits versus prospects. J Pharm Sci 97: 144–162. PMID: 17763452

30. Green M, Loewenstein PM (1998) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55: 1179–1188. PMID: 2849509

31. Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189–1193. PMID: 2849510

32. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569–1572. PMID: 10477521

33. Liu BR, Lin MD, Chiang HJ, Lee HJ (2012) Arginine-rich cell-penetrating peptides deliver gene into living human cells. Gene 505: 37–45. doi: 10.1016/j.gene.2012.05.053 PMID: 22669044

34. Tung CH, Weissleder R (2003) Arginine containing peptides as delivery vectors. Adv Drug Deliv Rev 55: 281–294. PMID: 12564961

35. Bolhassani A (2011) Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta 1816: 232–246. doi: 10.1016/j.bbacli.2011.07.006 PMID: 21840374

36. Futaki S, Ohashi W, Suzuki T, Niwa M, Tanaka S, et al. (2001) Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem 12: 1005–1011. PMID: 11716693

37. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, et al. (2000) Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6: 1253–1257. PMID: 11062537

38. Mitchell D, Kim D, Steinman L, Fathman C, Rothbard J (2000) Polyarginine enters cells more efficiently than other polycationic homopolymers. J Peptide Res 56: 318–325.

39. Shiryaev SA, Ratnikov BI, Chekanov AV, Sikora S, Rozanov DV, et al. (2006) Cleavage targets and the cleavage pattern of PACE4. FEBS Lett 580: 5213–5218. doi: 10.1016/j.febslet.2006.09.024

40. Remacle AG, Gawlik K, Golubkov VS, Cadwell GW, Liddington RC, et al. (2010) Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int J Biochem Cell Biol 42: 987–995. doi: 10.1016/j.biocel.2010.02.013 PMID: 20971070

41. Shiryaev SA, Remacle AG, Ratnikov BI, Nelson NA, Savinov AY, et al. (2007) Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem 282: 20847–20853. PMID: 17537721

42. Bassi DE, Mahloogi H, Klein-Szanto AJ (2000) The proprotein convertases furin and PACE4 play a significant role in tumor progression. Mol Carcinog 28: 63–69. PMID: 10900462

43. Sato H, Kinoshita TT, T., Nakayama K, Seiki M (1996) Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 393: 101–104. PMID: 8804434

44. Khatib AM, Siegfried G, Prat A, Luis J, Chrétien M, et al. (2001) Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem 276: 30686–30693.

45. Khatib AM, Siegfried G, Chrétien M, Metrakos P, Seidah NG (2002) Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 160: 1921–1935. PMID: 12057895

46. Shirazi AN, Paquin KL, Howlett NG, Mandal D, Parang K (2014) Cyclic peptide-capped gold nanoparticles for enhanced siRNA delivery. Molecules 19: 13319–13331. doi: 10.3390/molecules19091331 PMID: 25170952

47. Nasrolahi Shirazi A, Tiwari RK, Oh D, Sullivan B, Kumar A, et al. (2014) Cyclic peptide-selenium nanoparticles as drug transporters. Mol Pharm 11: 3631–3641. doi: 10.1021/mp500364a PMID: 25184366

48. Qian Z, Liu T, Liu YY, Briesewitz R, Barrios AM, et al. (2013) Efficient delivery of cyclic peptides into mammalian cells with short sequence motifs. ACS Chem Biol 8: 423–431. doi: 10.1021/cb3005275 PMID: 23130658
49. Oh D, Sun J, Nasrolahi Shirazi A, LaPlante KL, Rowley DC, et al. (2014) Antibacterial activities of amphiphilic cyclic cell-penetrating peptides against multidrug-resistant pathogens. Mol Pharm 11: 3528–3536. doi: 10.1021/mp5003027 PMID: 25157458

50. Mandal D, Nasrolahi Shirazi A, Parang K (2011) Cell-penetrating homochiral cyclic peptides as nuclear-targeting molecular transporters. Angew Chem Int Ed Engl 50: 9633–9637. doi: 10.1002/anie.201102572 PMID: 21919161

51. Shen Y, Yu W, Hay JG, Sauthoff H (2011) Expressed cell-penetrating peptides can induce a bystander effect, but passage through the secretory pathway reduces protein transduction activity. Mol Ther 19: 903–912. doi: 10.1038/mt.2010.283 PMID: 21179011